NNC0487-0111
DrugNNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors in a skinfold in the thigh.
Not Yet Recruiting
NCT Number: NCT07587710
A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in People With Reduced Liver Function and Normal Liver Function
The study is testing a new study medicine to treat people with overweight/obesity and type 2 diabetes. The aim of this study is to see if it is safe and to find out how it works in people with reduced liver function and people with normal liver function.
Not Yet Recruiting
Trial opening soon.
Get NotifiedKey information
Conditions
Age range
18 year–80 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 1
Primary location
Summit Clinical Research s.r.o., Bratislava, Slovakia
Loading trial locations.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Male or female (sex at birth).
- Age 18-80 years (both inclusive) at the time of signing informed consent.
- Participants with stable hepatic impairment classified as Child-Pugh grade A, B or C as assessed by the investigator. Stable hepatic impairment is defined as no clinically significant change in disease status, as judged by the investigator.
Exclusion criteria
- Known or suspected hypersensitivity to study intervention(s) or related products.
- Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using a highly effective contraceptive method.
Treatment and study plan
Primary outcomes
-
AUC0-∞: The area under the NNC0487-0111 plasma concentration-time curve from time 0 to infinity after a single dose
Time frame: From pre-dose on Day 1 up to Day 28
Measured as hours*nanomole per liter (nmol*h/L)
Secondary outcomes
-
Cmax: Maximum observed plasma NNC0487-0111 concentration after a single dose
Time frame: From pre-dose on Day 1 until Day 5
Measured as nanomoles per liter (nmol/L)
-
tmax: Time to maximum observed plasma NNC0487-0111 concentration after a single dose
Time frame: From pre-dose on Day 1 until Day 5
Measured as hour
-
t½,: Terminal half-life for NNC0487-0111 after a single dose
Time frame: From pre-dose on Day 1 up to Day 28
Measured as hour
-
Vz/F: Apparent volume of distribution of NNC0487-0111 after a single dose
Time frame: From pre-dose on Day 1 up to Day 28
Liter
-
CL/F: Apparent clearance of NNC0487-0111 after a single dose
Time frame: From pre-dose on Day 1 up to Day 28
Measured as liter per hour (L/h)
-
Number of treatment emergent adverse events (TEAEs)
Time frame: From pre-dose on Day 1 up to Day 28
Measured as number of events
Study contacts
Contact information is provided by the study sponsor or research team.
Sponsors and collaborators
Lead sponsor
Novo Nordisk A/S
Industry
Registry information
Official study title
A Study Investigating the Pharmacokinetic Properties, Safety and Tolerability of NNC0487-0111 in Participants With Various Degrees of Hepatic Impairment and Participants With Normal Hepatic Function
Important dates
- Study start
- 2026
- Primary completion
- 2027
- Study completion
- 2027
- First posted
- May 14, 2026
- Registry last updated
- May 14, 2026
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Not Yet Recruiting
A Study to Learn How the Study Medicine Called PF-08653945 is Taken up Into the Blood in Adults With Overweight or Obesity
NCT07725809
Body Weight, Healthy
Brussels, Bruxelles-capitale, Région de, Belgium
View Trial Details
Not Yet Recruiting
AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
NCT07720271
Body Weight, Nutrition Disorders
Anniston, Alabama, United States
View Trial Details
Not Yet Recruiting
AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose Weight
NCT07668401
Body Weight, Nutrition Disorders
Surat, Gujarat, India
View Trial Details
Not Yet Recruiting
A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight
NCT07710768
Body Weight, Nutrition Disorders
Cypress, California, United States
View Trial Details